Back to Authors

Loftus, Edward V.

https://orcid.org/0000-0001-7199-6851

A5056735741 | I1330342723

Mayo Clinic

Citations 298

S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S395-S395

10.14309/01.ajg.0000776936.46186.11

S778 A Cross-Sectional Evaluation of the Prevalence of Pulmonary Diseases in Patients With Inflammatory Bowel Disease

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S360-S361

10.14309/01.ajg.0000776644.58292.96

S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S359-S359

10.14309/01.ajg.0000776624.73243.66

S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S357-S358

10.14309/01.ajg.0000776620.39225.48

S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S357-S357

10.14309/01.ajg.0000776616.76910.14

S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S355-S357

10.14309/01.ajg.0000776612.28121.af

S763 A Cohort Study of the Age of Menopause in Female Patients With and Without Inflammatory Bowel Disease

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S352-S353

10.14309/01.ajg.0000776584.48281.9f

S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S348-S348

10.14309/01.ajg.0000776548.94565.6c

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S338-S338

10.14309/01.ajg.0000776480.66336.75

S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S313-S314

10.14309/01.ajg.0000776304.52681.bf